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Metformin Impairs Vascular Endothelial Recovery
After Stent Placement in the Setting of Locally
Eluted Mammalian Target of Rapamycin Inhibitors
Via S6 Kinase-Dependent Inhibition of Cell Proliferation
Anwer Habib, MD,* Vinit Karmali, MA,* Rohini Polavarapu, BA,* Hirokuni Akahori, MD, PHD,*
Masataka Nakano, MD,† Saami Yazdani, PHD,† Fumiyuki Otsuka, MD,† Kim Pachura, BS,*
Talina Davis,* Jagat Narula, MD, PHD,‡ Frank D. Kolodgie, PHD,† Renu Virmani, MD,†
Aloke V. Finn, MD*
Atlanta, Georgia; Gaithersburg, Maryland; and New York, New York
Objectives This study sought to examine the effect of oral metformin (Mf) therapy on endothelialization in the setting of
drug-eluting stents (DES).
Background Mf is a commonly used therapy in diabetic patients receiving DES. Mf and locally eluted mammalian target of
rapamycin (mTOR) inhibitors used in DES have convergent molecular signaling; however, the impact of this drug
interaction on stent endothelialization is unknown.
Methods We examined human endothelial aortic cells (HAECs) and a rabbit model of stenting to determine points on mo-
lecular convergence between these 2 agents and their impact on stent endothelialization.
Results Western blotting of HAECs treated with Mf and the mTOR inhibitor sirolimus and 14-day rabbit iliacs treated with
the combination of zotarolimus-eluting stents (ZES) and oral Mf demonstrated greater inhibition of S6 kinase
(S6K), a downstream effector of mTOR complex 1, than either treatment alone. HAEC proliferation was signifi-
cantly inhibited by Mf or sirolimus treatments alone and further reduced when they were combined. Knockdown
of S6K via short interfering RNA in HAECs impaired cell proliferation via a cyclin D1–dependent mechanism,
whereas its overexpression rescued the antiproliferative effects of both agents. Last, endothelialization and en-
dothelial cell proliferation at 14 days were assessed in rabbits receiving ZES or bare-metal stents and Mf or pla-
cebo by scanning electron microscopy and bromodeoxyuridine/CD31 labeling, respectively. Both endpoints were
inhibited by ZES treatment alone and were further reduced by the combination of Mf and ZES.
Conclusions Significant convergence of signaling occurs between Mf and locally delivered mTOR inhibitors at S6K. This fur-
ther impairs endothelial recovery/proliferation via an S6K-dependent mechanism. Patients receiving Mf in com-
bination with stents that elute mTOR inhibitors are potentially at increased risk of delayed endothelial healing
and stent thrombosis. (J Am Coll Cardiol 2013;61:971–80) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.018Coronary artery disease is a leading cause of death and
disability in patients with diabetes. Treatment strategies
aimed at reducing events in diabetic patients have in-
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Metformin, Endothelial Recovery, and mTOR March 5, 2013:971–80Although DES have dramati-
cally reduced restenosis rates, their
use has been associated with an in-
creased risk of late stent thrombosis,
especially in diabetic patients (2–5).
Mechanisms behind this phenome-
non remain unknown; however, the
primary substrate underlying these
cases is lack of endothelialization
(6,7). The majority of DES in clin-
ical use elute inhibitors of the mam-
malian target of rapamycin
(mTOR), a phosphatidylinositol
kinase-related family of serine/
threonine kinase, which include
sirolimus [SRL], everolimus
[EVL] and zotarolimus (8,9).
mTOR exists in 2 distinct protein
complexes with specific binding
partners, including raptor in mTOR
complex 1 (mTORC1) and rictor
in mTOR complex 2. The best
known mTORC1 substrates are
S6 kinase (S6K) and eIF4E-
binding proteins (4E-BP), whereas
mTOR complex 2 phosphorylates
the hydrophobic motif of Akt.
The delay in endothelialization
seen in stents that elute mTOR
inhibitors suggests a key role for
mTOR and its downstream ef-
fectors in distinct processes crit-
ical for endothelial recovery after
rterial injury. Of these processes, cell proliferation may be the
ost essential and likely the exclusive domain of S6K (10).
Because mTOR also integrates signals from upstream
athways such as insulin and senses cellular nutrient
tatus and energy levels (11), it is affected by antidiabetic
edications that alter insulin content and nutrient/
nergy levels (12). We previously showed the interaction
f the oral peroxisome proliferator–activated receptor 
agonist rosiglitazone with locally eluted SRL further
delays stent healing due to convergence of molecular
signaling (13).
Metformin (Mf), a biguinide, is the most widely used
oral diabetic agent and inhibits mitochondrial respiratory
chain complex I, altering the adenosine monophosphate–
to–adenosine triphosphate ratio, thus resulting in the
activation of 5’-adenosine monophosphate–activated pro-
tein kinase (AMPK) (14,15). AMPK activation by Mf
leads to the inhibition of mTORC1 (16) and its down-
stream effectors (i.e., S6K). Despite its clinical relevance,
it remains uncertain how this potential convergence in
molecular signaling between locally eluting mTOR in-
hibitors and systemic Mf could affect vascular endothelial
Abbreviations
and Acronyms
4E-BP  eIF4E binding
protein
AICAR  5-aminoimidazole-
4-carboxamide-1--D-
ribofuranosyl 3=,5= cyclic
monophosphate
AMPK  5’-adenosine
monophosphate–activated
protein kinase
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EVL  everolimus
HAEC  human aortic
endothelial cell
Mf  metformin
mTOR  mammalian target
of rapamycin
mTORC1  mammalian
target of rapamycin
complex 1
PECAM1  platelet
endothelial cell adhesion
molecule 1
S6K  S6 kinase
shRNA  short hairpin RNA
siRNA  short interfering
RNA
SRL  sirolimus
ZES  zotarolimus-eluting
stent(s)recovery after stent placement. cTo test our hypothesis that Mf in combination with
locally eluted mTOR inhibitors results in a significant delay
in endothelial recovery due to further modulation of mTOR
signaling cascades, we examined points of molecular con-
vergence between these 2 agents in cultured endothelial cells
and explored the consequences of this interaction on endo-
thelial cell proliferation, an essential cellular function
needed for re-endothelialization. We then modeled the
effects of this interaction on stent endothelialization and
endothelial proliferation in vivo in rabbits receiving oral Mf
or placebo in combination with zotarolimus-eluting stents
(ZES) or bare-metal stents (BMS).
Methods
Cell culture, immunoblotting, quantification of cell
proliferation/viability and apoptosis, quantitative polymerase
chain reaction, plasmid and short interfering RNA trans-
fection, and lentiviral transduction. Human aortic endo-
thelial cells (HAECs) (Cell Applications, San Diego, Cal-
ifornia) were maintained in endothelial cell growth medium,
and passages 2 and 8 were used for all experiments unless
otherwise specified. Short interfering RNA target sequences
are provided (Online Table 1). Further experimental details
are available in the Online Appendix.
Rabbit model of iliac artery stenting, assessment of
endothelialization, and endothelial cell proliferation.
New Zealand white male rabbits were given Mf (100
mg/kg/day orally), the dose based on body surface area
calculations of therapeutic human dosing (2 g/day), stents were
placed and removed 14 days post-procedure as previously
described (17). En face scanning electron microscopy was used
to assess stent endothelialization. Bromodeoxyuridine was
given 18 and 12 h before removal, and immunostaining of
bromodeoxyuridine was used to assess proliferation on stent
surfaces. See the Online Appendix for further details.
tatistical analysis. Statistical analysis was performed us-
ng JMP Pro version 10 (SAS Institute, Cary, North
arolina). All data were expressed as mean  SD. Differ-
ences were evaluated using an unpaired Student t test
etween 2 groups. For multiple group comparisons a 1- or
-way analysis of variance was used. If the variance ratio test
F test) was significant, a more detailed post hoc analysis of
ifferences between groups was made using a Tukey-
ramer honest significance difference test. A p value 0.05
as considered statistically significant. (See the Online
ppendix for further details.)
esults
o determine how Mf interacts with mTOR inhibitors at
he vascular endothelium, we examined their effects, alone
nd in combination with HAECs, on the activity of
ownstream effectors of mTOR signaling. First, to confirm
f-activated AMPK in HAECs, we demonstrated that the
f-treated HAECs increased AMPK phosphorylationompared with controls, whereas no effect was seen with
973JACC Vol. 61, No. 9, 2013 Habib et al.
March 5, 2013:971–80 Metformin, Endothelial Recovery, and mTORFigure 1 Downstream Products of Mammalian Target of Rapamycin Complex 1, But Not Complex 2,
Are Inhibited by Mf in Human Aortic Endothelial Cells
Western blotting was conducted for phospho-5’-adenosine monophosphate–activated protein kinase (AMPK) (A), phospho-S6 kinase (S6K) (B), phospho-eIF4E binding
protein (4E-BP) (C), and phospho-Akt (D) and densitometry values calculated. Densitometry was normalized to the total protein product (n  4 per group). Cont  con-
trol; Mf  metformin; SRL  sirolimus.Figure 2 Endothelial Cell Proliferation is Differentially Inhibited by Mf in Combination
With Mammalian Target of Rapamycin Inhibition Regardless of Glycemic Environment
(A) Human aortic endothelial cells (HAECs) were incubated in the presence of increasing doses of Mf (0 to 50 mmol/l) for 24 h, and cell proliferation was measured by
bromodeoxyuridine (BrdU) cell proliferation assay (n  4 per group). (B) HAECs were incubated in the presence of increasing doses of SRL (0 to 500 nmol/l) and everoli-
mus (EVL) (0 to 500 nmol/l) for 24 h, and proliferation was measured (n  4 per group). (C, D) HAECs were incubated in normoglycemic (NG) (5 mmol/l glucose) and
hyperglycemic (HG) (30 mmol/l) environments, respectively, for 48 h followed by exposure to Mf (30 mmol/l) and SRL (500 nmol/l)/EVL (500 nmol/l) alone or in combi-
nation for 24 h, and proliferation was measured (n  4 per group). Abbreviations as in Figure 1.
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Metformin, Endothelial Recovery, and mTOR March 5, 2013:971–80SRL alone (Fig. 1A). SRL groups (i.e., control and Mf)
showed inhibition of all downstream targets of mTOR (i.e.,
S6K, 4E-BP, and Akt); however, S6K phosphorylation was
differentially inhibited with SRL-Mf compared with SRL-
control (Fig. 1B). Mf alone inhibited S6K but did not
significantly inhibit Akt or 4E-BP activity (Figs. 1C and 1D).
ollectively, the significant observed interaction that occurs
etween Mf and SRL was at S6K.
Previous studies suggested a dominant role for
TORC1 and S6K in cell-cycle progression and prolif-
ration (18,19). Given the significant overlap in molec-
lar signaling observed between Mf and SRL at S6K, we
xamined their effects on processes likely involved in
ndothelialization. HAEC proliferation was observed to
ecrease in a dose-dependent manner with Mf, SRL, and
he SRL analog EVL, respectively (Figs. 2A and 2B).
he concentration of Mf (30 mmol/l) that inhibited 50%
f proliferation matched serum levels in patients receiv-
ng Mf therapy (20). We then compared the agents, in
ombination, both in normoglycemic (5 mmol/l) and
yperglycemic (30 mmol/l) conditions, respectively. The
ombination of SRL with Mf (SRL-Mf) resulted in the
reatest inhibition of cell proliferation while there was also
significant inhibition with the combination of EVL with Mf
EVL-Mf) compared with either agent alone, regardless of the
lycemic condition (Figs. 2C and 2D).
Cell viability under each treatment was also assessed using a
Figure 3 Inhibition of Cell Proliferation by Mf Is AMPK Depende
(A, B) Increasing doses of 5-aminoimidazole-4-carboxamide-1--D-ribofuranosyl
A-769662 (0 to 1,000 mol/l), a selective AMPK activator, were incubated wit
HAECs were incubated with AICAR (2 mmol/l), A-769662 (100 mol/l) and SR
(n  4 per group). (D) HAECs were transfected with short interfering RNA (siRN
treated with increasing doses of Mf (0 to 30 mmol/l) for 24 h. Cell proliferatio
Figures 1 and 2.-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-ide assay and was decreased in a dose-dependent manner by
f and SRL/EVL, in addition to being differentially de-
reased with the combination of Mf and SRL/EVL compared
ith either agent alone (Online Figs. 1A and 1B).
Apoptosis was assessed using a combination of annexin V
nd propidium iodide staining and were seen to increase in a
ose-dependent manner with all agents; however, although the
ombination of EVL and Mf did significantly increase apo-
tosis, the combination of SRL and Mf did not (Online Figs.
C and 1D). This suggests that the interaction of Mf with
RL/EVL acts predominantly on proliferation/viability rather
han on apoptosis.
ffect of Mf on endothelial cell proliferation is AMPK
ependent. To observe the effect of AMPK activation, selec-
ive AMPK activators 5-aminoimidazole-4-carboxamide-1--
D-ribofuranosyl 3=,5= cyclic monophosphate (AICAR) and
A-769662, were used (21,22). Dose-dependent inhibi-
tion of proliferation with AICAR or A-769662 was
observed with each agent alone in addition to further
suppression of proliferation when combined with SRL
(Figs. 3A and 3B). Transfection with short interfering
RNA (siRNA) for AMPK (1/2), rescued HAEC pro-
liferative ability despite treatment with increasing doses
of Mf, suggesting that Mf requires AMPK for its
antiproliferative effect (Fig. 3C, Online Fig. 2). Trans-
fection with short interfering for AMPK (a1/2) rescued
cyclic monophosphate (AICAR) (0 to 10 mmol/l), an AMP mimetic, and
Cs for 24 h, and cell proliferation was measured (n  4 per group). (C)
nmol/l) alone or in combination for 24 h, and proliferation was measured
AMPK 1/2 or nontargeting, scrambled siRNA (Scr) and were subsequently
measured at 24 h with a BrdU assay (n  4 per group). Abbreviations as innt
3=,5=
h HAE
L (500
A) for
n wasHAEC proliferative ability despite treatment with in-
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March 5, 2013:971–80 Metformin, Endothelial Recovery, and mTORcreasing doses of Mf, suggesting that Mf requires AMPK
for its antiproliferative effect.
Effect of Mf on endothelial recovery and proliferation is
dependent on the mTORC1/S6K axis. Given the inhibi-
tion of S6K and cell proliferation observed with the com-
bination of Mf and ZES, we decided to examine whether
suppression of mTORC1 alone could affect endothelial
stent-strut coverage using a novel in vitro stent strut assay.
HAECs were transduced with short hairpin RNA (shRNA)
for raptor, a vital protein component of mTORC1, or
scrambled shRNA, and allowed to grow on an in vitro
stent-strut coverage model for 2 weeks. Expression of
platelet endothelial cell adhesion molecule 1 (PECAM1)/
CD31, a commonly used endothelial marker, was measured
from the stent surface. The raptor shRNA group demon-
strated a significant decrease in PECAM1/CD31 expres-
sion compared with scrambled shRNA-treated cells
(Fig. 4A, Online Fig. 2). Stents were also immunostained
for PECAM1/CD31 with representative examples from
Figure 4 Genetic Knockdown of Mammalian Target of Rapamyc
Its Downstream Effector, Inhibits Stent Endothelializa
(A) HAECs were transduced, with raptor/mammalian target of rapamycin complex
grow on an in vitro stent strut coverage model for 2 weeks. Stents were immunos
endothelial coverage was assessed with confocal microscopy and on-cell enzyme-l
focal images are shown at 20 magnification. HAECs were transfected with siRNA
sured with a BrdU cell-proliferation assay at 24 h (n  4 per group, inset). (B to D
treated with Mf (0 to 30 mmol/l) or SRL (0 to 10 nmol/l) or EVL (0 to 10 nmol/l),
assay (n  4 per group). Abbreviations as in Figures 1 through 3.each group shown (Fig. 4A).To assess which downstream effector of mTORC1
(i.e., S6K or 4E-BP) is critical for proliferation, HAECs
were transfected with siRNA for S6K1 and 4E-BP3 to
target their major catalytic isoforms (23), respectively, or
nontargeting, scrambled siRNA (Scr). Proliferation was
significantly decreased in HAECs transfected with
siRNA for S6K1 compared with 4E-BP3 (Fig. 4A).
To determine whether the antiproliferative effect of
Mf is mediated via S6K, we overexpressed either a
constitutively active wild-type S6K or an SRL-resistant
mutant via plasmid transfection in HAECs and then
treated cells with increasing doses of Mf (Fig. 4B, Online
ig. 2). Overexpression of either form of S6K mitigated
he antiproliferative effect of Mf. Overexpression of S6K
as repeated with increasing doses of SRL/EVL con-
rming that their inhibition of cell proliferation occurs
ia S6K (Figs. 4C and 4D) (18).
Endothelial cell proliferation by S6K is mediated via
cyclin D1 regulation. Control of endothelial cell prolifer-
omplex 1 and S6K,
nd Endothelial Cell Proliferation, Respectively
rt hairpin RNA (shRNA) or nontargeting scrambled shRNA (Scr), and allowed to
with anti-CD31/platelet endothelial cell adhesion molecule 1 antibody, and
immunosorbent assay, normalized to Scr (n  4 per group). Representative con-
6K1, 4E-BP3, or nontargeting, scramble siRNA (Scr). Cell proliferation was mea-
Cs overexpressing wild-type (WT) or a sirolimus-resistant mutant (MT) S6K were
ctively, for 24 h and cell proliferation measured with a BrdU cell-proliferationin C
tion a
1 sho
tained
inked
for S
) HAE
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Metformin, Endothelial Recovery, and mTOR March 5, 2013:971–80tional control of cyclin D1, a member of the cyclin
protein family that is involved in cell-cycle G1/S phase
progression (10). HAECs treated with Mf and SRL,
alone and in combination, demonstrated decreased pro-
tein expression of cyclin D1, although the SRL-Mf group
inhibited cyclin D1 to the greatest extent (Fig. 5A). To
demonstrate a direct connection between S6K inhibition
and cyclin D1 mRNA regulation, we used an siRNA
against S6K1. Knockdown of S6K1 significantly de-
creased cyclin D1 mRNA expression (Fig. 5B). Last,
overexpression of cyclin D1 via plasmid transfection
mitigated the effects of increasing doses of both Mf and
SRL on cell proliferation (Figs. 5C and 5D).
ffect of Mf on the mTOR signaling pathway in rabbits
eceiving DES and oral Mf. Given the effects of Mf on
he mTOR signaling pathway seen in HAECs in vitro, we
xamined whether these same interactions occur in vivo in
abbits receiving BMS or DES (ZES, ENDEAVOR stent,
edtronic, Minneapolis, Minnesota) in the presence of oral
f (100 mg/kg/day) or placebo for 14 days (Online Fig. 3).
otarolimus, like EVL, is a semisynthetic analogue of siroli-
us designed for increased lipophilicity but preserving its
pecificity for mTOR inhibition (9).
As seen in vitro, increased AMPK activation in the
rterial wall of all Mf groups was observed compared with
ontrols (Fig. 6A). Next, we examined S6K/4E-BP and
kt phosphorylation, downstream effectors of mTORC1
Figure 5 S6K Controls Proliferation by Regulating Cyclin D1 Ex
(A) HAECs were incubated with SRL (500 nmol/l) or Mf (30 mmol/l), alone and
normalized to beta-actin levels were measured by densitometry (n  4 per grou
with siRNA for S6K1 and nontargeting, scrambled siRNA (Scr). Cyclin D1 mRNA
Cyclin D1 mRNA expression measured by quantitative polymerase chain reactio
overexpressed in HAECs via plasmid transfection and exposed to increasing do
ation measured at 24 h (n  4 per group). Abbreviations as in Figures 1 thround mTOR complex 2, respectively. S6K was inhibited to ehe greatest extent in the ZES-Mf group compared with
ll other groups (Fig. 6B). Interestingly, the BMS-Mf
roup demonstrated reduced S6K phosphorylation; how-
ver, no effect on 4E-BP or Akt was seen (Figs. 6C and
D). All ZES groups (i.e., control and Mf) showed
nhibition of Akt and S6K phosphorylation but not
E-BP. The latter finding is consistent with the known
ilder and transient effects of mTOR inhibitors on
E-BP (24). These data confirm that the significant
verlap in mTOR signaling at S6K in the arterial wall in
ivo in animals receiving oral Mf and ZES was seen in
itro with SRL and Mf.
ral Mf further impairs endothelial cell proliferation
nd coverage and in rabbits receiving ZES. A combina-
ion of PECAM1/CD31 for endothelial staining and bro-
odeoxyuridine labeling of proliferating cells was used to
ocalize proliferating endothelial cells on the stent surface in
ur animal model by confocal microscopy (Fig. 7). The
ES-control group had significantly less proliferation com-
ared with BMS groups, consistent with the antiprolifera-
ive effects of mTOR inhibition. Similar to the in vitro
ndings, there was significantly less proliferation in the
ombination ZES-Mf group compared with BMS groups
BMS-control and BMS-Mf) and numerically less than the
ES-control group (Table 1).
Last, we explored the effects of this interaction on
ndothelial coverage after stent placement by scanning
sion
mbination, and Western blots performed for cyclin D1. Relative expression
) HAECs were transfected with siRNA for S6K1 and HAECs were transfected
ssion measured by quantitative polymerase chain reaction (n  4 per group).
targeting, scrambled siRNA (Scr) (n  4 per group). (C, D) Cyclin D1 was
f Mf (0 to 30 mmol/l) or SRL (0 to 10 nmol/l), respectively, with cell prolifer-pres
in co
p). (B
expre
n non
ses o
gh 3.lectron microscopy (Fig. 8). ZES-control significantly
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March 5, 2013:971–80 Metformin, Endothelial Recovery, and mTORimpaired endothelial coverage compared with BMS-
control, as previously reported (17). Oral Mf decreased
endothelial coverage in BMS (BMS-Mf) compared with
BMS-control; however, this was not statistically signifi-
cant. Conversely, there was a significant decrease in
coverage with ZES and systemic Mf treatment (ZES-
Mf) compared with ZES placement alone (ZES-control)
as well as BMS (BMS-control and BMS-Mf) (Table 2).
Discussion
Although DES using mTOR inhibitors prevent resteno-
sis, they also result in delayed stent endothelialization, a
finding that implicates mTOR and its downstream effec-
tors as critical in this process. Although local drug
delivery minimizes systemic toxicity, it does not eliminate
the potential for drug– drug interactions with systemic
medications. Clinical studies of sirolimus and newer
generation everolimus-eluting stents suggest differential
effects in nondiabetic and diabetic patients, with the
latter having significantly higher rates of late stent
thrombosis (2–5), a phenomenon related to delayed stent
endothelialization (6,7). This study indicates that Mf
interacts with mTOR signaling and when combined with
Figure 6 Downstream Effectors of Mammalian Target of Rapam
But Not Complex 2, Are Differentially Inhibited in Anim
Representative Western blots and densitometry of 14-day rabbit iliac arteries sten
absence of Mf (100 mg/kg/day) for phospho-AMPK (A), an upstream inhibitor of m
downstream effectors of mammalian target of rapamycin complex 1, and phospho
tometry was normalized to the total protein product (n  3 per group). Abbreviatiolocally eluted mTOR inhibitors resulted in further sup-pression of endothelial proliferation both in our in vivo
and in vitro models. A convergence in molecular signal-
ing between these 2 agents was found at S6K via an
AMPK-dependent mechanism, which our data demon-
strate is critical for endothelial proliferation via control of
cyclin D1. These findings suggest that patients receiving
oral Mf and DES that elute mTOR inhibitors may be at
increased risk of delayed stent healing.
Previous studies showed important roles for Akt and
4E-BPs in cell proliferation (23,25). We found that the
effect of knockdown of 4E-BP and Akt (data not shown)
on HAEC proliferation was relatively little compared
with S6K. The antiproliferative effect of Mf has been
reported in multiple cell types, especially in response to
injury or malignancy, with the suppressed downstream
mediators appearing to be cell type and context specific
(10,26 –29). Our data, however, suggest that S6K plays a
dominant role in endothelial proliferation.
Although AMPK activation and mTOR inhibition
may affect apoptosis individually, their combined effect
was variable, and both were a function of their action on
Akt activity and environmental context (30 –33). Al-
though SRL/EVL proapoptotic action is consistent with
Complex 1,
Receiving ZES and Oral Mf
th a bare-metal stent (BMS) or zotarolimus-eluting stent (ZES) in the presence or
alian target of rapamycin complex 1, phospho-S6K (B) and phospho-4EBP (C),
), a downstream effector of mammalian target of rapamycin complex 2. Densi-
in Figure 1.ycin
als
ted wi
amm
-Akt (D
ns asits suppression of Akt, Metformin, via activation of
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Metformin, Endothelial Recovery, and mTOR March 5, 2013:971–80LKB1/AMPK, may also promote proapoptosis-mediated
pathways (34). Eventual feedback activation of Akt, via
combined mTORC1 suppression by Mf and SRL/EVL
may occur, leading to variable effects on apoptosis when
agents are combined (Online Fig. 4) (35).
Clinical relevance. Mf is the most widely used antidiabetes
medication in the world and is associated with improved
endothelial function in diabetic patients (36). We suggest,
however, that Mf may have a direct deleterious effect on
Figure 7 Stent Surface Endothelial Cell Proliferation Is Impaire
Confocal microscopy was conducted on 14-day whole-mount stented (BMS or ZES
immunofluorescence for platelet endothelial cell adhesion molecule 1/CD31 (gree
arrows indicate examples of proliferating endothelial cells. Abbreviations as in Fig
Quantification of 14-DayEndo heli l Cell Proliferation (%)Table 1 Quantification of 14-DayEndothelial Cell Proliferation (%)
Group %, Mean  SD
p Value
vs. BMS
Control
vs. BMS
Mf
vs. ZES
Control
BMS-control (n  3) 48.3 6.8
BMS-Mf (n  3) 43.0 7.9 0.6629
ZES-control (n  3) 20.1 0.9 0.0011* 0.0043*
ZES-Mf (n  3) 11.6 3.9 0.0002* 0.0006* 0.3112*Statistically significant (p  0.05).
BMS  bare-metal stent(s); Mf  metformin; ZES  zotarolimus-eluting stent(s).endothelial recovery after stent-induced injury because of its
effects on proliferation in the setting of DES that elute
mTOR inhibitors. Because poor stent endothelialization
has been shown as an underlying substrate for late stent
thrombosis in both pathological and clinical studies, this
study suggests that long-term Mf therapy may augment the
potential risk of late in-stent thrombosis. In a pooled
analysis from several randomized clinical trials of EVL-
eluting stents, Stone et al. (3) recently reported a differential
clinical response to EVL-eluting stents in patients with and
without diabetes with significantly increased stent throm-
bosis and myocardial infarction rates in diabetic patients not
treated with insulin compared with those without diabetes
at 2 years. Prospective studies are needed to determine
whether the impairment of endothelial coverage occurs in
patients treated with the combination of systemic Mf and
local mTOR inhibition, corresponding to an increase risk of
late in-stent thrombosis.
Study limitations. The use of a nonatherosclerotic, non-
diabetic animal model of stenting may have underestimated
the effect of Mf in combination with ZES on endothelial
he Greatest Extent in Rabbits Treated With ZES-Mf
al segments in the presence or absence of Mf (100 mg/kg/day) using dual
BrdU (red). Representative figures are shown at 100 magnification. White
and 6.d to t
) arteri
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ures 1healing.
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This is the first study to elucidate the effects of oral Mf
on endothelial recovery in the setting of stent placement.
Patients receiving Mf in combination with newer gener-
ation DES that use mTOR inhibitors are potentially at
increased risk of delayed stent endothelialization and
stent thrombosis.
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Figure 8
Endothelial Stent Strut Coverage
Is Significantly Impaired in ZES in
Combination With Oral Mf in the Rabbit Iliac Model
Representative scanning electron micrographs (15 magnification) of 14-day
BMS and ZES in the presence and absence of oral Mf (100 mg/kg/day) treat-
ment. Note the significantly decreased endothelial strut coverage in the ZES-Mf
group versus all others.
Quantification of 14-Day EndothelialCoverage by Scanning Electr n Microscopy (%)Table 2 Quantification of 14-D y EndothelialCoverage by Scanning Electron Microscopy (%)
Group %, Mean  SD
p Value
vs. BMS
Control
vs. BMS
Mf
vs. ZES
Control
BMS-control (n  6) 79.7 18.3
BMS-Mf (n  5) 59.0 18.2 0.1979
ZES-control (n  5) 43.2 20.5 0.0087* 0.4468
ZES-Mf (n  6) 13.3 6.4 0.0001* 0.0012* 0.0359**Statistically significant (p  0.05).
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